Neil E. Stahl - 16 Dec 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role: EVP Research and Development
Signature: /s/**Neil Stahl
Issuer symbol: REGN
Transactions as of: 16 Dec 2022
Net transactions value: $0
Form type: 4
Filing time: 20 Dec 2022, 15:08:43 UTC
Previous filing: 13 Dec 2022
Next filing: 23 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	REGN	Common Stock	Award	$0	+1,101	+2.1%	$0.000000	53,100	16 Dec 2022	Direct	F1
holding	REGN	Common Stock						5,814	16 Dec 2022	By 401(k) Plan
holding	REGN	Common Stock						4,605	16 Dec 2022	by Spouse as Trustee

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	REGN	Non-Qualified Stock Option (right to buy)	Award	$0	+4,063		$0.000000	4,063	16 Dec 2022	Common Stock	4,063	$726.53	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 16, 2024 and 50% on December 16, 2026.
F2	The stock option award vests in four equal annual installments, commencing one year after the date of grant.